The Department of Veterans Affairs intends to negotiate a sole-source procurement for TheraSphere Y-90 doses, specifically targeting the treatment of unresectable primary Hepatocellular Carcinoma, with Boston Scientific. This procurement is justified under FAR 13.5 and 41 U.S.C. § 1901, indicating that only one source can fulfill the agency's requirements due to the specialized nature of the treatment, which involves the use of glass microspheres containing a radioactive isotope (Y-90) injected directly into the liver to combat liver cancer. Interested parties are encouraged to express their capability to meet this requirement by the deadline of October 15, 2024, at 9 AM EST, although no solicitation is currently available. All inquiries should be directed to Contracting Officer Robert Blasko at robert.blasko@va.gov.